Slide 1: Non-Renounceable Entitlement Offer & Top Up Facility
Non- Renounceable Entitlement Offer & Top Up Facility 17 March 2023
Slide 2: Disclaimer
Disclaimer This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) and is provided for general information purposes only. No party other than OncoSil has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, repre
Slide 3: Company Overview
Company Overview Capital Structure Share Price Chart ASX Code OSL Share Price (at 16 March 2023) $0.031 Shares on Issue 989,242,262 Market Capitalisation $30.67m Cash in bank (31 December 2022) $5.76m Top 20 shareholders 33.74% Board of Directors Otto Buttula Nigel Lange Brian Leedman Non-Executive
Slide 4: Key Details of the Offer
Indicative Timetable of Entitlement Offer Key Details of the Offer Offer to Eligible Shareholders • 1 New Share for every 1 Share held at the Record Date at the Issue Price plus: • 1 Option for every 1 New Share subscribed under the Offer; • Option means a New Option to purchase a Share with an exer
Slide 5: Indicative Timetable of Entitlement Offer
Indicative Timetable of Entitlement Offer Important dates* Entitlement Offer announcement Friday, 17 March 2023 Record Date (to determine Entitlement of Eligible Shareholders to participate in the Offer) Wednesday, 22 March 2023 Opening Date of Rights Issue Offer – Dispatch of the Prospectus and Ent
Slide 6: Use of Funds
Use of Funds The Entitlement Offer seeks to raise a maximum of $9.9m and will be used for the following purposes: Use of funds* Sales and marketing resources to support commercialisation activities for the OncoSil device in Europe and the United Kingdom $4.4m Clinical trial expenditure to expand the
Slide 7: How to Apply
How to Apply You may only take up all of part of Contact your Entitlement by For any queries concerning your Entitlement please contact the Company’s Share registry on 1300 737 760 • Making payment by Bpay® corresponding the (within Australia) or +61 2 9290 9600 (outside Australia. component (part o
Slide 8: Introduction
Introduction The prognosis for pancreatic cancer patients has remained almost unchanged for over 40 years1 with a reported five-year survival rate for the disease of 10%2 Changes in survival, 1971-72 to 2010-11 0% 25% 50% 75% 100% All Cancers Incidence Testis Malignant Melanoma Prostate Hodgkin Lymp
Slide 9: OncoSil Medical's targeted approach delivers a positive impact in pancreatic cancer
OncoSil Medical’s targeted approach delivers a positive impact in the treatment of pancreatic cancer, aimed at extending the length and quality of life for patients 9 • Investor Presentation • 17 March 2023
Slide 10: Executive Summary
Executive Summary OncoSil™ is a commercial-stage • Implanted device delivers targeted radiation to pancreatic tumour breakthrough device delivering targeted radiotherapy for pancreatic cancer • Breakthrough designation received in the EU/UK, US and Singapore • Experienced management, sales, clinical
Slide 11: Board and Management Team with Experience and Expertise
Board and Management Team with Experience and Expertise Otto Brian Buttula Leedman Non-executive Non-executive Chairman Director Extensive experience in Experienced company director, investment research, funds Investor Relations specialist and management and IT and biotechnology entrepreneur. previo
Slide 12: OncoSil Device
OncoSil™ Device Overview • OncoSil™ is intended for the treatment of locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. • OncoSil™ is a single-use brachytherapy device comprised of microparticles and a diluent. • OncoSil™ is implanted directly into a
Slide 13: What we have accomplished
What we have accomplished Experienced CE Marking Innovation Funding Enabled HDE pathway team in place obtained (NUB) approved for bile duct cancer German funding in the US of the OncoSil™ device Application submitted to FDA PanCO Study Breakthrough device Current market approvals completed designati
Slide 14: PanCO results showing compelling evidence of downstaging
PanCO results showing compelling evidence of downstaging OncoSil™ converted patients with unresectable locally advanced pancreatic cancer (LAPC) to resection, transforming their prognosis and substantially extending survival What did the PanCO study show? ≥32 months Adding OncoSil™ to 1 in 3 patient
Slide 15: Sales and training activities to date
Sales and training activities to date During the year, the OncoSil™ team has progressed on key site start-up activities Key experienced sales, marketing and training team in place OncoSil™ launched in: – no need for any expansion of the team in the near term Pamplona Distributors have been identifie
Slide 16: This is where we are today
This is where we are today Market access and clinical development supporting sales activities Sales team fully Detailed health Identifying programs Clinical Development engaged with economic and market for fully funded, pathway targeted Key Opinion access analysis. government • Preparation for Leade
Slide 17: Commercial expansation opportunties
Commercial expansation opportunties Future work required to expand opportunities for the OncoSilTM device Expansion of current label Generate clinical evidence to access to include FOLFIRINOX chemo public payer markets globally Alternative device delivery Improvements to the OncoSilTM device methods
Slide 18: Nigel Lange
Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com OncoSil Medical Ltd www.oncosil.com T: +49 30 300 149 3043